TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32178662

Group type: EXPERIMENTAL
Intervention: AOK‐Junior care program
Number of subjects: 63000

Group type: EXPERIMENTAL
Intervention: Secondary preventive measures
Number of subjects: 63000

Group type: EXPERIMENTAL
Intervention: Health economic evaluation
Number of subjects: 63000

Group type: EXPERIMENTAL
Intervention: Qualitative and quantitative primary data collection
Number of subjects: 63000

Group type: EXPERIMENTAL
Intervention: Cross-sectional design
Number of subjects: 63000

Group type: EXPERIMENTAL
Intervention: Longitudinal section design
Number of subjects: 63000

Group type: EXPERIMENTAL
Intervention: Focus groups with parents and pediatricians
Number of subjects: 63000
Study: 34595995

Group type: EXPERIMENTAL
Intervention: KBP-5074
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33032566

Group type: EXPERIMENTAL
Intervention: Outpatient THA (discharged on the same day as surgery)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard inpatient THA (minimum of one night in hospital)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Outpatient THA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard inpatient THA
Number of subjects: 0
Study: 36237580

Group type: EXPERIMENTAL
Intervention: Traditional Chinese and Western medicine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Western medicine
Number of subjects: 45
Study: 33905746

Group type: EXPERIMENTAL
Intervention: Tea Tree Oil (TTO) shampoo
Number of subjects: 40

Group type: COMPARATOR
Intervention: Regular eyelid shampoo
Number of subjects: 40
Study: 32064729

Group type: EXPERIMENTAL
Intervention: MODY (GCK-MODY)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: MODY (HNF-MODY)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Non-MODY (T2D)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: HNF-MODY
Number of subjects: 448
Study: 35486196

Group type: EXPERIMENTAL
Intervention: Continuous Treatment (CT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Discontinuous Treatment (DT)
Number of subjects: 55
Study: 32803728

Group type: EXPERIMENTAL
Intervention: Good Pain Management (GPM) program
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Strong opioids in GPM arm
Number of subjects: 51
Study: 35276942

Group type: EXPERIMENTAL
Intervention: MIU (drinking water produced from deep sea water)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Mineral water (control)
Number of subjects: 41
Study: 34013966

Group type: EXPERIMENTAL
Intervention: Multicomponent Intervention (MCI)
Number of subjects: 2645

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 2645
Study: 35272176

Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg modified release once daily (QD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vildagliptin 50 mg immediate release twice daily (BID)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 30
Study: 33963366

Group type: EXPERIMENTAL
Intervention: Lichtenstein under local anaesthesia (LLA)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Total extraperitoneal repair (TEP) under general anaesthesia
Number of subjects: 384
Study: 32860414

Group type: EXPERIMENTAL
Intervention: Thoracoscopic surgical ablation (SA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Catheter ablation (CA)
Number of subjects: 120
Study: 35152580

Group type: EXPERIMENTAL
Intervention: Tiaoshen acupuncture combined with artificial tears
Number of subjects: 70

Group type: COMPARATOR
Intervention: Artificial tears alone (0.1% sodium hyaluronate eye drop, 3 times a day)
Number of subjects: 70
Study: 33320381

Group type: EXPERIMENTAL
Intervention: Low-dose ticagrelor (LD group, 45 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-dose ticagrelor (SD group, 90 mg twice daily)
Number of subjects: 0
Study: 35572937

Group type: EXPERIMENTAL
Intervention: miCBT
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: RLX
Number of subjects: 121

Group type: COMPARATOR
Intervention: WLC
Number of subjects: 121
Study: 34224266

Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo or standard care not specified)
Number of subjects: 0
Study: 35885456

Group type: EXPERIMENTAL
Intervention: Low frequency WBV (16–26 Hz) associated to ST (G1)
Number of subjects: 51

Group type: COMPARATOR
Intervention: WBV sham (G2)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Nonintervention control (G3)
Number of subjects: 51
Study: 34610135

Group type: COMPARATOR
Intervention: mOPV2
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: nOPV2-c1
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: nOPV2-c2
Number of subjects: 621
Study: 32986828

Group type: EXPERIMENTAL
Intervention: Black race
Number of subjects: 9719

Group type: EXPERIMENTAL
Intervention: Hispanic ethnicity and Asian race
Number of subjects: 9719

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy
Number of subjects: 9719
Study: 32270634

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS) at Yingxiang (LI 20) and Yintang (GV 29) 10 min before anesthesia induction until the end of operation.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group received general anesthesia directly.
Number of subjects: 40
Study: 35894078

Group type: EXPERIMENTAL
Intervention: Liraglutide + Metformin (L + M)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric banding
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Metformin (MET)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355
Study: 33047732

Group type: EXPERIMENTAL
Intervention: S-P-BG group (5% STMP, 5% PAA, 0.5 g/L BG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no pretreatment)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BG group (0.5 g/L BG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: S-P-BG group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BG group
Number of subjects: 30
Study: 33338413

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 4304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4304
Study: 32459375

Group type: EXPERIMENTAL
Intervention: Low-dose TKIs
Number of subjects: 77

Group type: COMPARATOR
Intervention: Full-dose TKIs
Number of subjects: 77
Study: 33949051

Group type: EXPERIMENTAL
Intervention: Educational movie on chronic pain management (10 minutes duration)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Control group (no educational movie)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Educational movie on chronic pain management
Number of subjects: 381
Study: 32816358

Group type: EXPERIMENTAL
Intervention: Predisaster PTEs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Models including PTSS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Models including PD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Models including all pre- and postdisaster PTEs
Number of subjects: 0
Study: 33241721

Group type: EXPERIMENTAL
Intervention: ubrogepant 50 mg
Number of subjects: 1799

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1799
Study: 32100497

Group type: EXPERIMENTAL
Intervention: Acupuncture at acupoints (Tiantu, Danzhong, Zhongwan, Zusanli, Taichong, Neiguan) plus esomeprazole (20 mg, twice a day) and mosapride (5 mg, three times a day) for 14 days.
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional treatment with esomeprazole (20 mg, twice a day) and mosapride (5 mg, three times a day) for 14 days.
Number of subjects: 84
Study: 33874955

Group type: EXPERIMENTAL
Intervention: Chiropractic care
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 185
Study: 35606561

Group type: EXPERIMENTAL
Intervention: GRAVo score model including race
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: GRAVo score model excluding race
Number of subjects: 291

Group type: COMPARATOR
Intervention: Comparison of both GRAVo score models
Number of subjects: 291
Study: 33839013

Group type: EXPERIMENTAL
Intervention: Rh antigen typing using a fully automated system based on hemagglutination
Number of subjects: 3000
Study: 35141776

Group type: EXPERIMENTAL
Intervention: Endocuff Vision colonoscopy (EVC)
Number of subjects: 1178

Group type: COMPARATOR
Intervention: Standard colonoscopy (SC)
Number of subjects: 1178
Study: 34536115

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery
Number of subjects: 842

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 842
Study: 35983530

Group type: EXPERIMENTAL
Intervention: Injectable salvianolic acid treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional alteplase and butalbital treatment
Number of subjects: 90
Study: 33653317

Group type: EXPERIMENTAL
Intervention: HIPEC with cisplatin
Number of subjects: 50

Group type: COMPARATOR
Intervention: SOX regime alone (Control)
Number of subjects: 50
Study: 32108161

Group type: EXPERIMENTAL
Intervention: Povidone-Iodine irrigation
Number of subjects: 193

Group type: COMPARATOR
Intervention: Control (no povidone-iodine irrigation)
Number of subjects: 193
Study: 36087842

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (four times daily over eight weeks)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 61
Study: 32163139

Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (RIC) using an automated autoRIC™ cuff on the upper arm inflated to 200 mmHg for 5 min and deflated for 5 min for four cycles
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 100
Study: 35081366

Group type: EXPERIMENTAL
Intervention: Fascial therapy intervention (3 weeks, 45-minute weekly sessions)
Number of subjects: 69
Study: 33655978

Group type: EXPERIMENTAL
Intervention: Laser acupuncture (LA)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Sham laser acupuncture (SLA)
Number of subjects: 92
Study: 36018547

Group type: EXPERIMENTAL
Intervention: Camel milk (200 milliliters daily for 2 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 33941940

Group type: EXPERIMENTAL
Intervention: Single preoperative oral dose of 500mg amoxicillin
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Single preoperative oral dose of 400mg metronidazole
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional therapy (500mg of Amoxicillin BD, 400mg of metronidazole and painkillers postoperatively)
Number of subjects: 19
Study: 35414293

Group type: EXPERIMENTAL
Intervention: 2-for-1 price incentive for fruits and vegetables (F&V)
Number of subjects: 0
Study: 34390625

Group type: EXPERIMENTAL
Intervention: 15-minute compression schedule
Number of subjects: 1244

Group type: COMPARATOR
Intervention: Other compression rates and slopes (not specified)
Number of subjects: 1244
Study: 33981141

Group type: EXPERIMENTAL
Intervention: Rengalin (2 tablets 2 times daily for 4 weeks)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo (2 tablets 2 times daily for 4 weeks)
Number of subjects: 238
Study: 36086686

Group type: EXPERIMENTAL
Intervention: Estrogen and progesterone sequential therapy combined with Foley balloon treatment
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group treatment plan
Number of subjects: 86
Study: 33860709

Group type: EXPERIMENTAL
Intervention: Cannabidiol (600 mg)
Number of subjects: 13
Study: 33115517

Group type: EXPERIMENTAL
Intervention: PCCs
Number of subjects: 160

Group type: COMPARATOR
Intervention: PBMNCs
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: PBDSCs transplantation
Number of subjects: 160
Study: 33353385

Group type: EXPERIMENTAL
Intervention: Occupational Performance Coaching (OPC)
Number of subjects: 36
Study: 32854573

Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (TKI)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (COVID-19 patients without cancer)
Number of subjects: 16
Study: 36258248

Group type: EXPERIMENTAL
Intervention: Baclofen (10, 30, 60, or 90 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (vitamin D3)
Number of subjects: 0
Study: 34582477

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 400 mg/day for 10 days
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study: 34142111

Group type: EXPERIMENTAL
Intervention: CT-P17 (100 mg/ml) continued every 2 weeks (Q2W)
Number of subjects: 607

Group type: COMPARATOR
Intervention: Reference adalimumab continued every 2 weeks (Q2W)
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: CT-P17 (100 mg/ml) switched from reference adalimumab
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: CT-P17 continued
Number of subjects: 607

Group type: COMPARATOR
Intervention: Reference adalimumab continued
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: CT-P17 switched from reference adalimumab
Number of subjects: 607

Group type: COMPARATOR
Intervention: CT-P17 and reference adalimumab
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Joint damage progression
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Mean trough serum adalimumab concentrations
Number of subjects: 607
Study: 32613664

Group type: EXPERIMENTAL
Intervention: ERL monotherapy (n = 27)
Number of subjects: 53

Group type: COMPARATOR
Intervention: MIST (n = 26)
Number of subjects: 53
Study: 36386549

Group type: EXPERIMENTAL
Intervention: Risk-based stratified care using Keele's STarT MSK Tool and risk-matched treatments
Number of subjects: 1211

Group type: COMPARATOR
Intervention: Usual care (advice, education, medication, referrals)
Number of subjects: 1211
Study: 36413059

Group type: EXPERIMENTAL
Intervention: Game-based mobile application (used for 7 days)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Traditional teaching methods (control group)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Game-based mobile application (experimental group)
Number of subjects: 105
Study: 33309516

Group type: EXPERIMENTAL
Intervention: Work Limitation Questionnaire 25‐item version (WLQ‐25)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Revised Work Limitation Questionnaire (after item reduction and response merging)
Number of subjects: 315
Study: 32727451

Group type: EXPERIMENTAL
Intervention: Intervention group using the Patient Preferences for Patient Participation (4Ps) tool
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 35291806

Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma (PRP)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Cord blood platelet-rich plasma (PRPc)
Number of subjects: 71

Group type: COMPARATOR
Intervention: PRP
Number of subjects: 71

Group type: COMPARATOR
Intervention: PRPc
Number of subjects: 71
Study: 33977309

Group type: EXPERIMENTAL
Intervention: Aortic valve leaflet fusion length measurement
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Flow asymmetry, circumferential wall shear stress, and presence of vortices
Number of subjects: 120
Study: 35835552

Group type: EXPERIMENTAL
Intervention: Enhanced recovery after surgery plus pulmonary rehabilitation
Number of subjects: 374

Group type: COMPARATOR
Intervention: Enhanced recovery after surgery alone (control)
Number of subjects: 374
Study: 33228458

Group type: EXPERIMENTAL
Intervention: Willingness to enroll in a clinical trial for a COVID-19 vaccine
Number of subjects: 2768

Group type: COMPARATOR
Intervention: Willingness to agree to a randomized placebo-controlled study
Number of subjects: 2768

Group type: EXPERIMENTAL
Intervention: Factors associated with willingness to participate
Number of subjects: 2768
Study: 33283612

Group type: EXPERIMENTAL
Intervention: FAmily‐CEntered (FACE®) pACP intervention
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Families living with HIV
Number of subjects: 105
Study: 36173208

Group type: EXPERIMENTAL
Intervention: Health education + personalised diet guidance + intensive resistance exercise (Group C)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Health education + personalised diet guidance (Group B)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Centralised education alone (Group A)
Number of subjects: 78
Study: 32517806

Group type: EXPERIMENTAL
Intervention: Multicomponent hypertension control program
Number of subjects: 1584

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 1584
Study: 35641354

Group type: EXPERIMENTAL
Intervention: 3D virtual reality (VR) using a head-mounted display
Number of subjects: 117

Group type: COMPARATOR
Intervention: 2D virtual reality (VR) on a laptop screen
Number of subjects: 117
Study: 33476377

Group type: EXPERIMENTAL
Intervention: Weight-Bearing (WB) assessments (squat-bilateral, squat-unilateral, lunge positions)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Lunge position
Number of subjects: 51

Group type: COMPARATOR
Intervention: Nonweight-bearing (NWB) assessments (hip external rotation [HER], hip extension [HEXT], hip abduction [HAB])
Number of subjects: 51
Study: 36376921

Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine (AL)
Number of subjects: 558

Group type: COMPARATOR
Intervention: artesunate-amodiaquine (ASAQ)
Number of subjects: 558
Study: 36241352

Group type: EXPERIMENTAL
Intervention: Psilocybin-assisted therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 32964282

Group type: EXPERIMENTAL
Intervention: Midface lift plus facial lipofilling
Number of subjects: 56

Group type: COMPARATOR
Intervention: Midface lift only
Number of subjects: 56
Study: 32127283

Group type: EXPERIMENTAL
Intervention: Intranasal DEX (2 μg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intranasal DEX-KET (2 μg/kg DEX + 1 mg/kg KET)
Number of subjects: 60
Study: 33200456

Group type: EXPERIMENTAL
Intervention: Interpersonal relational role analysis (IRRA)
Number of subjects: 8
Study: 33199806

Group type: EXPERIMENTAL
Intervention: Neutral Electrolyzed Water (NEW) 58 ppm
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: NaClO 35 ppm
Number of subjects: 3

Group type: COMPARATOR
Intervention: Saline Solution (SS)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Neutral Electrolyzed Water (NEW)
Number of subjects: 3
Study: 33916940

Group type: EXPERIMENTAL
Intervention: Atlantic diet intervention group
Number of subjects: 720

Group type: COMPARATOR
Intervention: Control group (habitual lifestyle)
Number of subjects: 720
Study: 32541299

Group type: EXPERIMENTAL
Intervention: Conjugated estrogen vaginal cream (applied for at least 5 weeks preoperatively and continued twice-weekly through 12 months postoperatively)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Conjugated estrogen vaginal cream
Number of subjects: 197
Study: 33933853

Group type: EXPERIMENTAL
Intervention: Pimavanserin 34 mg once daily
Number of subjects: 459
Study: 36342475

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75mg once daily
Number of subjects: 5438

Group type: COMPARATOR
Intervention: Aspirin 100mg once daily
Number of subjects: 5438
Study: 33793290

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control beverages
Number of subjects: 83
Study: 32447856

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Baihui (GV20) and Shuigou (GV26) points in addition to routine western medicine treatment.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Routine western medicine treatment (control group).
Number of subjects: 70
Study: 34757701

Group type: EXPERIMENTAL
Intervention: Increased perceived stress (PSS-10 scores)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Single marital status, high-risk pregnancy, IL-2, TNF-α
Number of subjects: 247

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 247
Study: 32812785

Group type: EXPERIMENTAL
Intervention: Pea gravel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beech wood chips
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spruce wood chips
Number of subjects: 0

Group type: COMPARATOR
Intervention: Soil
Number of subjects: 0
Study: 33004398

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitisation and Reprocessing (EMDR) therapy
Number of subjects: 20
Study: 33550553

Group type: EXPERIMENTAL
Intervention: Endosulfan 0.75 ppb/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endosulfan 1.0 ppb/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endosulfan 1.5 ppb/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no exposure to endosulfan)
Number of subjects: 0
Study: 36123633

Group type: EXPERIMENTAL
Intervention: Preamble (improved question wording)
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Standard weight question
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Weight-specific question
Number of subjects: 1400

Group type: COMPARATOR
Intervention: No preamble (control condition)
Number of subjects: 1400
Study: 34144591

Group type: EXPERIMENTAL
Intervention: QUICK TAPE
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-Dye Taping
Number of subjects: 20
Study: 32911462

Group type: EXPERIMENTAL
Intervention: CTA-guided PCI
Number of subjects: 60

Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 60
Study: 35019237

Group type: EXPERIMENTAL
Intervention: Triamcinolone-impregnated packing
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normal saline-soaked packing (Control)
Number of subjects: 22
Study: 33724614

Group type: EXPERIMENTAL
Intervention: Oxygen–ozone therapy (O2–O3)
Number of subjects: 20
Study: 34129127

Group type: EXPERIMENTAL
Intervention: 4-week adaptive biofeedback (ABF) training
Number of subjects: 42

Group type: COMPARATOR
Intervention: fixed biofeedback (FBF) training
Number of subjects: 42
Study: 34338469

Group type: EXPERIMENTAL
Intervention: Surgical resection of primary breast cancer (26 mastectomy and 19 breast conserving surgery)
Number of subjects: 45
Study: 32725861

Group type: EXPERIMENTAL
Intervention: Parent Led Therapist Supervised Articulation Therapy (PLAT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Routine speech therapy intervention
Number of subjects: 44
Study: 35901382

Group type: COMPARATOR
Intervention: Baseline pain
Number of subjects: 688

Group type: COMPARATOR
Intervention: Incident pain
Number of subjects: 688

Group type: COMPARATOR
Intervention: Pain persistence
Number of subjects: 688